Biocon Gets A New Group CEO As Aflibercept Approval Arrives
Peter Bains Named As New Chief; Yesafili Biosimilar Is Europe’s First Eylea Rival
Biocon has named Peter Bains as its new group CEO, as the firm’s Biocon Biologics business confirmed that its aflibercept biosimilar to Eylea had become the first to receive a formal European approval.
